Market Highlights
The Global Bronchitis Market is Expected to grow at a CAGR of 5.3% during the forecast period.The
infection in the airways of lungs (bronchi) is known as bronchitis, which is of
two types, namely, acute and chronic bronchitis. Acute bronchitis resolves
within two to three weeks while chronic bronchitis is the condition when a
cough exists for at least three months and at least two years in a row.
Smoking, viruses such as flu and bacteria, inhalation of irritating fumes or
dust are the major causes of chronic bronchitis. Chest X-ray, sputum tests, and
pulmonary function tests are various tests performed for the diagnosis of acute
as well as chronic bronchitis.
High prevalence of lung diseases
such as Chronic Obstructive Pulmonary Disease (COPD), bronchitis, asthma, and
others are the major factor driving the growth of the market. Further, there is
a huge demand for diagnostic tests for bronchitis and other lung diseases. The
treatment includes administration of drugs such as antibiotics,
anti-inflammatory drugs, bronchodilators, and mucolytics.
Taste the market data and market
information presented through more than 55 market data tables and figures
spread over 101 pages of the project report. Avail the in-depth table of
content (TOC) & market synopsis on “Bronchitis market research
report–Global forecast till 2023.”
Major Players in the Bronchitis
Market:
Some of the key players in the
global market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer
Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug
Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.
Regional Analysis
The market for bronchitis is
found to be increasing in Americas, which is driven by growing awareness about
risk factors of COPD and bronchitis and rising emphasis on healthy lifestyle
and prevention of lung diseases. In the U.S., the bronchitis market is fueled
by the presence of major market players and extensive use of diagnostic services.
The rapid growth in diagnostic and treatment services also accelerates the
growth of the market.
In Europe, the major factors
accelerating the market are extensive research and development in the field of
respiratory diseases and increase in the number of players in the market
manufacturing drugs for the treatment of diseases. Germany is the largest
contributor to the market growth.
In Asia Pacific, the market is
driven by the rising prevalence of chronic diseases including respiratory
diseases and increasing environmental pollution.
In the Middle East and Africa,
rising awareness about lung diseases among adults and development of the
healthcare sector drive the growth of the market.
Segmentation
The global bronchitis market is
segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market
is segmented into acute bronchitis and chronic bronchitis.
On the basis of diagnosis, the
market is segmented into chest X-ray, sputum tests, and pulmonary function
tests.
On the basis of treatment, the
market is segmented into drugs and oxygen therapy. Drugs is further segmented
into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics.
On the basis of end-user, the
market is segmented into hospitals, clinics, pharmacies, research institutes,
and others.
No comments:
Post a Comment